These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 38018436)

  • 21. PI(4,5)P2 Is Translocated by ABCA1 to the Cell Surface Where It Mediates Apolipoprotein A1 Binding and Nascent HDL Assembly.
    Gulshan K; Brubaker G; Conger H; Wang S; Zhang R; Hazen SL; Smith JD
    Circ Res; 2016 Sep; 119(7):827-38. PubMed ID: 27514935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses.
    van Capelleveen JC; Kastelein JJ; Zwinderman AH; van Deventer SJ; Collins HL; Adelman SJ; Round P; Ford J; Rader DJ; Hovingh GK
    J Clin Lipidol; 2016; 10(5):1137-1144.e3. PubMed ID: 27678430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A thumbwheel mechanism for APOA1 activation of LCAT activity in HDL.
    Cooke AL; Morris J; Melchior JT; Street SE; Jerome WG; Huang R; Herr AB; Smith LE; Segrest JP; Remaley AT; Shah AS; Thompson TB; Davidson WS
    J Lipid Res; 2018 Jul; 59(7):1244-1255. PubMed ID: 29773713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imbalance of APOB Lipoproteins and Large HDL in Type 1 Diabetes Drives Atherosclerosis.
    Kothari V; Ho TWW; Cabodevilla AG; He Y; Kramer F; Shimizu-Albergine M; Kanter JE; Snell-Bergeon J; Fisher EA; Shao B; Heinecke JW; Wobbrock JO; Lee WL; Goldberg IJ; Vaisar T; Bornfeldt KE
    Circ Res; 2024 Jul; 135(2):335-349. PubMed ID: 38828596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected by treatment with LCAT.
    Koukos G; Chroni A; Duka A; Kardassis D; Zannis VI
    Biochem J; 2007 Aug; 406(1):167-74. PubMed ID: 17506726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors controlling nascent high-density lipoprotein particle heterogeneity: ATP-binding cassette transporter A1 activity and cell lipid and apolipoprotein AI availability.
    Lyssenko NN; Nickel M; Tang C; Phillips MC
    FASEB J; 2013 Jul; 27(7):2880-92. PubMed ID: 23543682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of apolipoprotein A-I on ATP-binding cassette transporter A1-mediated efflux of macrophage phospholipid and cholesterol: formation of nascent high density lipoprotein particles.
    Liu L; Bortnick AE; Nickel M; Dhanasekaran P; Subbaiah PV; Lund-Katz S; Rothblat GH; Phillips MC
    J Biol Chem; 2003 Oct; 278(44):42976-84. PubMed ID: 12928428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct Roles of Apolipoproteins A1 and E in the Modulation of High-Density Lipoprotein Composition and Function.
    Filou S; Lhomme M; Karavia EA; Kalogeropoulou C; Theodoropoulos V; Zvintzou E; Sakellaropoulos GC; Petropoulou PI; Constantinou C; Kontush A; Kypreos KE
    Biochemistry; 2016 Jul; 55(27):3752-62. PubMed ID: 27332083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel compound inhibits reconstituted high-density lipoprotein assembly and blocks nascent high-density lipoprotein biogenesis downstream of apolipoprotein AI binding to ATP-binding cassette transporter A1-expressing cells.
    Lyssenko NN; Brubaker G; Smith BD; Smith JD
    Arterioscler Thromb Vasc Biol; 2011 Nov; 31(11):2700-6. PubMed ID: 21836073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-density lipoprotein remodeling by phospholipid nanoparticles improves cholesterol efflux capacity and protects from atherosclerosis.
    Kudinov VA; Torkhovskaya TI; Zakharova TS; Morozevich GE; Artyushev RI; Zubareva MY; Markin SS
    Biomed Pharmacother; 2021 Sep; 141():111900. PubMed ID: 34328100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of apolipoprotein (Apo) A-I structure on nascent high density lipoprotein (HDL) particle size distribution.
    Vedhachalam C; Chetty PS; Nickel M; Dhanasekaran P; Lund-Katz S; Rothblat GH; Phillips MC
    J Biol Chem; 2010 Oct; 285(42):31965-73. PubMed ID: 20679346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein.
    Favari E; Lee M; Calabresi L; Franceschini G; Zimetti F; Bernini F; Kovanen PT
    J Biol Chem; 2004 Mar; 279(11):9930-6. PubMed ID: 14701812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-Density Lipoprotein Particle Concentration and Size Predict Incident Coronary Artery Disease Events in a Cohort With Type 1 Diabetes.
    Costacou T; Vaisar T; Miller RG; Davidson WS; Heinecke JW; Orchard TJ; Bornfeldt KE
    J Am Heart Assoc; 2024 Jul; 13(14):e034763. PubMed ID: 38958152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Roles of Reconstituted High-Density Lipoprotein Nanoparticles in Cardiovascular Disease: A New Paradigm for Drug Discovery.
    Huang J; Wang D; Huang LH; Huang H
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ATP binding cassette A1 (ABCA1) mediates microparticle formation during high-density lipoprotein (HDL) biogenesis.
    Hafiane A; Genest J
    Atherosclerosis; 2017 Feb; 257():90-99. PubMed ID: 28129550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles.
    Vedhachalam C; Duong PT; Nickel M; Nguyen D; Dhanasekaran P; Saito H; Rothblat GH; Lund-Katz S; Phillips MC
    J Biol Chem; 2007 Aug; 282(34):25123-30. PubMed ID: 17604270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.
    Yvan-Charvet L; Kling J; Pagler T; Li H; Hubbard B; Fisher T; Sparrow CP; Taggart AK; Tall AR
    Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1430-8. PubMed ID: 20448206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The carboxy-terminal region of apoA-I is required for the ABCA1-dependent formation of alpha-HDL but not prebeta-HDL particles in vivo.
    Chroni A; Koukos G; Duka A; Zannis VI
    Biochemistry; 2007 May; 46(19):5697-708. PubMed ID: 17447731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dietary stearic acid and palmitic acid do not differently affect ABCA1-mediated cholesterol efflux capacity in healthy men and postmenopausal women: A randomized controlled trial.
    van Rooijen MA; Plat J; Blom WAM; Zock PL; Mensink RP
    Clin Nutr; 2021 Mar; 40(3):804-811. PubMed ID: 32900520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased cholesterol efflux capacity in metabolic syndrome: Relation with qualitative alterations in HDL and LCAT.
    Lucero D; Sviridov D; Freeman L; López GI; Fassio E; Remaley AT; Schreier L
    Atherosclerosis; 2015 Sep; 242(1):236-42. PubMed ID: 26232163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.